Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer

Journal of Clinical Oncology

Volumn 18, Issue 19, 2000, Pages 3390-3399

  Gatzemeier, Ulrich ^a   Von Pawel, Joachim ^a   Gottfried, Maya ^a   Ten Velde, G P M ^a   Mattson, Karin ^a   DeMarinis, Filipo ^a   Harper, Peter ^a   Salvati, Franco ^a   Robinet, Gilles ^a   Lucenti, Antonio ^a   Bogaerts, Jan ^a   Gallant, Gilles ^a  

^a KRANKENHAUS GROSSHANSDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; PACLITAXEL;

ADULT; AGED; ARTHRALGIA; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MYALGIA; NAUSEA; NEPHROTOXICITY; OTOTOXICITY; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VOMITING;

EID: 0034306321     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.19.3390     Document Type: Article

References (47)

1. Lung cancer: Worldwide variation in occurrence and proportion attributable to tobacco use
2. Rationale for the treatment of non-small cell lung cancer
3. Non-small cell lung carcinoma: Current and future therapeutic management
4. Future directions in the treatment of non-small cell lung cancer
5. Management (chemotherapy/best supportive care) of advanced-stage non-small cell lung cancer
6. The Non-Small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomized clinical trials
7. Phase II study of Taxol in patients with untreated advanced non-small cell lung cancer
8. Phase II study of Taxol, merbarone and prixantrone in stage IV non-small cell lung cancer: The Eastern Cooperative Oncology Group results
9. Phase II study with paclitaxel for the treatment of advanced inoperable non-small cell lung cancer
10. A randomized study of cisplatin versus cisplatin plus vindesine for non-small cell lung carcinoma
11. Treatment of advanced non-small cell lung cancer (NSCLC): The UMBRIA cooperative study
12. A randomized study of cisplatin (DDP) versus DDP plus vindesine in advanced non-small cell lung cancer with an analysis of prognostic factors using multivariate methods
13. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in treatment of advanced non-small cell lung cancer: A Southwest Oncology Group study
14. Cisplatin versus cisplatin plus etoposide in the treatment of advanced non-small cell lung cancer
15. Phase II randomized trial comparing high-dose cisplatin with moderate-dose cisplatin and carboplatin in patients with advanced non-small cell lung cancer
16. A confidence interval for the median survival time
17. Average partial association in three-way contingency tables: A review and discussion of alternative tests
18. Combining dependent tests with incomplete repeated measurements
19. Phase II study with paclitaxel (Taxol) in advanced non-small cell lung cancer (NSCLC)
20. Single-agent paclitaxel by 3-hour infusion in the treatment of non-small cell lung cancer: Links between p53 and K-ras gene status and chemosensitivity
21. Phase II study of 3-hour infusion of paclitaxel in patients with previously untreated stage III and IV non-small cell lung cancer: West Japan Lung Cancer Group
22. Phase II study of patients with metastatic nonsmall cell carcinoma of the lung treated with paclitaxel by 3-hour infusion
23. Paclitaxel by 1-hour infusion: An active drug in metastatic non-small cell lung cancer
24. Paclitaxel single agent in the first-line treatment of advanced NSCLC
25. A phase II study of paclitaxel in patients with non-small cell lung cancer
26. Phase II study of 3-hour infusion of paclitaxel in previously untreated non-small cell lung cancer
27. Paclitaxel/cisplatin in advanced non-small cell lung cancer (NSCLC)
28. Paclitaxel by 96-hour continuous infusion in combination with cisplatin: A phase I trial in patients with advanced lung cancer
29. Preliminary results of a phase II study of paclitaxel and cisplatin in patients with non-small cell lung cancer
30. Phase I/II of biweekly paclitaxel (Taxol) and cisplatin in non-small cell lung cancer (NSCLC)
31. Phase II study of paclitaxel and cisplatin in patients with non-small cell lung cancer
32. Paclitaxel plus carboplatin in advanced non-small cell lung cancer: A phase II trial
33. Paclitaxel and carboplatin in combination in the treatment of advanced non-small cell lung cancer: A phase II toxicity, response, and survival analysis
34. Phase I trial, including pharmacokinetic and pharmacodynamic correlations, of combination paclitaxel and carboplatin in patients with metastatic non-small cell lung cancer
35. A phase I study of paclitaxel plus carboplatin in untreated patients with advanced non-small cell lung cancer
36. Phase I study of paclitaxel on a 3-hour schedule followed by carboplatin in untreated patients with stage IV non-small cell lung cancer
37. Paclitaxel 3-hour infusion given alone and combined with carboplatin: Preliminary results of dose-escalation trials
38. Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer: The European Cancer Centre
39. Phase II trial of paclitaxel and carboplatin as first line treatment in advanced non small cell lung cancer (NSCLC)
40. Paclitaxel and carboplatin in inoperable non-small-cell lung cancer: A phase II study
41. Phase I/II study of paclitaxel and carboplatin in advanced non-small cell lung cancer
42. Paclitaxel (1-hour) and carboplatin (area under the concentration-time curve 7.5) in advanced non-small cell lung cancer: A phase II study of the Fox Chase Cancer Center and its network
43. Phase II of a one hour paclitaxel infusion in combination with carboplatin for advanced non-small cell cancer
44. One-hour paclitaxel plus carboplatin in the treatment of advanced non-small cell lung cancer: Results of a multicentre, phase II trial
45. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer
46. Randomized study of paclitaxel-cisplatin versus cisplatin-etoposide in patients with advanced non-small cell lung cancer
47. Phase III trial comparing etoposide (E) cisplatin (C) versus taxol (T) with cisplatin-G-CSF (G) versus taxol-cisplatin in advanced non-small cell lung cancer: An Eastern Cooperative Oncology Group (ECOG) trial